Cargando…

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Huseni, Mahrukh, Totpal, Klara, Du, Changchun, Dalpozzo, Katie, Zhu, Jing, Rishipathak, Deepali, McNamara, Erin, Jonshtone, Bernadette, Hegde, Priti S, Rhee, Ina, Damico-Beyer, Lisa, Kim, Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292550/ http://dx.doi.org/10.1186/2051-1426-2-S3-P253

Ejemplares similares

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer
por: Ziai, James, et al.
Publicado: (2014)

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
por: Kim, Tae Won, et al.
Publicado: (2022)

Prevalence analysis of OX40-positive cell populations in solid tumors
por: Ziai, James, et al.
Publicado: (2015)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Zhang, Jing, et al.
Publicado: (2022)

CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
por: Huseni, Mahrukh A., et al.
Publicado: (2023)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies
por: Griffiths, Jordana, et al.
Publicado: (2020)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
por: Zhang, Di, et al.
Publicado: (2016)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
por: Sturgill, Elizabeth R., et al.
Publicado: (2021)

Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors
por: Scherwitzl, Iris, et al.
Publicado: (2020)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Antitumor efficacy of multi-target in situ vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers
por: Proskurina, Anastasia S., et al.
Publicado: (2023)

Regulation of A1 by OX40 Contributes to CD8(+) T Cell Survival and Anti-Tumor Activity
por: Lei, Fengyang, et al.
Publicado: (2013)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models
por: Pieper, Alexander A., et al.
Publicado: (2021)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
por: Turaj, Anna H., et al.
Publicado: (2018)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

Modern Trends in Imaging X: Spectral Imaging in Preclinical Research and Clinical Pathology
por: Levenson, Richard, et al.
Publicado: (2012)

STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors
por: Akporiaye, Emmanuel T, et al.
Publicado: (2013)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy
por: Liang, Shizhong, et al.
Publicado: (2023)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
por: Fu, NanNan, et al.
Publicado: (2021)

The Chiral Pool in the Pictet–Spengler Reaction for the Synthesis of β-Carbolines
por: Dalpozzo, Renato
Publicado: (2016)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Preclinical Studies in Anti-Trypanosomatidae Drug Development
por: Perdomo, Cintya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qggoh1cbenhv22msfo7mn9rk9t